Amarin sued Hikma over a generic version of Vascepa, pointing to Hikma's labeling, website, and press releases as encouragement to prescribe the drug for a patented cardiovascular use that the label had carved out. The Supreme Court considered whether those statements cleared the federal pleading standard for induced infringement.
